Loading…
IXHL
Incannex Healthcare Inc.
NASDAQ· Healthcare· Drug Manufacturers - Specialty & Generic· CUSIP 45333F208
$3.64-1.35%Price as of Aug 29, 18:45 UTC · updated once a day, after the close
Key metrics
- Market cap
- $43.55M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$16.62
- ROE
- -117.17%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 2.81
- 52-week high
- $20.64
- 52-week low
- $2.49
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.7% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Year-end price | $3.32 | $10.74 | $63.60 | $139.20 | |
| P/S | — | — | 1447.4x | 3116.9x | — |
| P/B | 3.4x | 0.6x | 9.3x | 3.3x | 3.5x |
| EPS | -$1.66 | -$40.82 | -$34.50 | -$99.60 | |
| Profit margin | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ALGSAligos Therapeutics, Inc. | $6.91 | — | 1.4x | — | -113.59% | $43.15M |
| VERUVERU Inc | $2.50 | — | 1.5x | — | -64.54% | $42.63M |
| EDSAEdesa Biotech, Inc. | $4.62 | — | 112.7x | — | -122.93% | $44.54M |
| MLSSMilestone Scientific Inc | $0.50 |
About the company
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is also developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. Incannex Healthcare Inc. is headquartered in Sydney, Australia.
- 12
- Sydney, Australia
Company description provided by Yahoo Finance.